Identification of hepatitis C virus NS5A inhibitors

Journal of Virology

Volumn 84, Issue 1, 2010, Pages 482-491

  Lemm, Julie A ^a   O'Boyle II, Donald ^a   Liu, Mengping ^a   Nower, Peter T ^a   Colonno, Richard ^a,b   Deshpande, Milind S ^a,c   Snyder, Lawrence B ^a   Martin, Scott W ^a   St Laurent, Denis R ^a   Serrano Wu, Michael H ^a,d   Romine, Jeffrey L ^a   Meanwell, Nicholas A ^a   Gao, Min ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Presidio Pharmaceuticals Inc   (United States)

^c Achillion Pharmaceuticals   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; BMS 665; BMS 824; BMS 858; GLUTAMINE; HISTIDINE; LEUCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN INHIBITOR; TYROSINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA VIRUS; DRUG DETERMINATION; DRUG SELECTIVITY; ENZYME ACTIVE SITE; GENE MAPPING; GENE MUTATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPLICON; RNA VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SURVIVAL;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE; DRUG EVALUATION, PRECLINICAL; GENOTYPE; HEPACIVIRUS; HUMANS; PHOSPHORYLATION; REPLICON; THIAZOLIDINES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS C VIRUS;

EID: 72849113547     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01360-09     Document Type: Article

References (36)

1. Appel, N., U. Herian, and R. Bartenschlager. 2005. Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. J. Virol. 79:896-909.
2. Behrens, S. E., L. Tomei, and R. DeFrancesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22. (Pubitemid 26020384)
3. Berg, T., S. B. Cohen, J. Desharnais, C. Sonderegger, D. J. Maslyar, J. Goldberg, D. L. Boger, and P. K. Vogt. 2002. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 99:3830-3835.
4. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
5. Cheng, G., A. Montero, P. Gastaminza, C. Whitten-Bauer, S. F. Wieland, M. Isogawa, B. Fredericksen, S. Selvarajah, P. A. Gallay, M. R. Ghadiri, and F. V. Chisari. 2008. A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 105:3088-3093.
6. Conte, I., C. Giuliano, C. Ercolani, F. Narjes, U. Koch, M. Rowley, S. Altamura, R. De Francesco, P. Neddermann, G. Migliaccio, and I. Stansfield. 2009. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg. Med. Chem. Lett. 19:1779-1783.
7. Egger, D., B. Wolk, R. Gosert, L. Bianchi, H. E. Blum, D. Moradpour, and K. Bienz. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:5974-5984. (Pubitemid 34556292)
8. Failla, C., L. Tomei, and R. DeFrancesco. 1994. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68:3753-3760. (Pubitemid 24177400)
9. Foster, G., and P. Mathurin. 2008. Hepatitis C virus therapy to date. Antivir. Ther. 13(Suppl. 1):3-8.
10. Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U. S. A. 90:10583-10587.
11. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1385-1395. (Pubitemid 23067645)
12. Guo, J., V. V. Bichko, and C. Seeger. 2001. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:8516-8523. (Pubitemid 32768956)
13. Holler, T. P., T. Parkinson, and D. C. Pryde. 2009. Targeting the nonstructural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin. Drug Discov. 4:3.
14. Huang, L., J. Hwang, S. D. Sharma, M. R. Hargittai, Y. Chen, J. J. Arnold, K. D. Raney, and C. E. Cameron. 2005. Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J. Biol. Chem. 280:36417-36428.
15. Kaneko, T., Y. Tanji, S. Satoh, M. Hijikata, S. Shinichi, K. Kimura, and K. Shimotohno. 1994. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205:320-326.
16. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624. (Pubitemid 32381503)
17. Lemm, J. A., M. Liu, R. E. Rose, R. Fridell, D. R. O'Boyle II, R. Colonno, and M. Gao. 2005. Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology 48:183-191. (Pubitemid 41201509)
18. Lohmann, V., F. Korner, A. Dobierzewska, and R. Bartenschlager. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449. (Pubitemid 32094702)
19. Lohmann, V., F. Korner, J.-O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNA in a hepatoma cell line. Science 285:110-113. (Pubitemid 29307577)
20. Love, R. A., O. Brodsky, M. J. Hickey, P. A. Wells, and C. N. Cronin. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403.
21. MacDonald, A., and M. Harris. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502.
22. Miyanari, Y., K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, M. Zayas, R. Bartenschlager, T. Wakita, M. Hijikata, and K. Shimotohno. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097.
23. Neddermann, P., A. Clementi, and R. De Francesco. 1999. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J. Virol. 73:9984-9991.
24. Neddermann, P., M. Quintavalle, C. Di Pietro, A. Clementi, M. Cerretani, S. Altamura, L. Bartholomew, and R. De Francesco. 2004. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J. Virol. 78:13306-13314. (Pubitemid 39507835)
25. Nettles, R., C. Chien, E. Chung, A. Persson, M. Gao, M. Belema, N. A. Meanwell, M. P. DeMicco, T. C. Marbury, R. Goldwater, P. Northup, J. Coumbis, W. K. Kraft, M. R. Charlton, J. C. Lopez-Talavera, and D. Grasela. 2008. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study, abstr. LB12. Abstr. 59th Annu. Meet. Am. Assoc. Study Liver Dis., San Francisco, CA.
26. O'Boyle, D. R., II, P. T. Nower, J. A. Lemm, L. Valera, J.-H. Sun, K. Rigat, R. Colonno, and M. Gao. 2005. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49:1346-1353.
27. Quintavalle, M., S. Sambucini, C. Di Pietro, R. De Francesco, and P. Neddermann. 2006. The isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J. Virol. 80:11305-11312. (Pubitemid 44706570)
28. Ripka, A., J. A. Campbell, A. C. Good, P. M. Scola, N. Sin, and B. Venables. March 2004. Hepatitis C virus inhibitors. U.S. patent 20040048802 A1.
29. Romine, J. L., S. W. Martin, L. B. Snyder, M. Serrano-Wu, M. Deshpande, D. Whitehouse, J. Lemm, D. O'Boyle, M. Gao, and R. Colonno. February 2007. Iminothiazolidinones as inhibitors of HCV replication. U.S. patent 7,183,302 B2.
30. Tai, C.-L., W.-K. Chi, D.-S. Chen, and L.-H. Hwang. 1996. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 70:8477-8484. (Pubitemid 26378425)
31. Tanji, Y., T. Kaneko, S. Satoh, and K. Shimotohno. 1995. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69:3980-3986.
32. Tellinghuisen, T. L., J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279:48576-48587.
33. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2005. Structure of the zinc-binding domain of an essential replicase component of hepatitis C virus reveals a novel fold. Nature 435:374-379.
34. Tellinghuisen, T. L., K. L. Foss, and J. Treadaway. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4:e1000032.
35. Tsantrizos, Y. S., G. Bolger, P. Bonneau, D. R. Cameron, N. Goudreau, G. Kukolj, S. R. LaPlante, M. Llinas-Brunet, H. Nar, and D. Lamarre. 2003. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 42:1355-1360.
36. Yanagi, M., R. Purcell, S. Emerson, and J. Bukh. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U. S. A. 94:8738-8743.